Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Twist Bioscience Corporation TWST

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throu...


Recent & Breaking News (NDAQ:TWST)

Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program

Business Wire September 2, 2020

Twist Bioscience Synthetic DNA Stores New Netflix Original Series 'BIOHACKERS'

Business Wire August 20, 2020

Twist Bioscience Reports Third Quarter Fiscal 2020 Financial Results

Business Wire August 6, 2020

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

Business Wire August 4, 2020

Twist Bioscience to Report Fiscal 2020 Third Quarter Financial Results on Thursday, August 6, 2020

Business Wire July 30, 2020

Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19

Business Wire July 28, 2020

Twist Bioscience Appoints Erin Smith Senior Vice President, Government Affairs and Public Policy

Business Wire July 23, 2020

Twist Bioscience Launches Synthetic Controls for Respiratory Viruses

Business Wire July 22, 2020

Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

Business Wire July 16, 2020

Twist Bioscience Customer Vanderbilt University Medical Center (VUMC) Announces Publication of Positive Preclinical Results on Neutralizing Antibodies as a Potential Therapy for Preventing and Treating COVID-19

Business Wire July 15, 2020

Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities

Business Wire July 8, 2020

Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line

Business Wire June 30, 2020

Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls

Business Wire June 11, 2020

Twist Bioscience Partners with Serimmune to Identify SARS-CoV-2 Therapeutic Antibody Candidates

PR Newswire June 9, 2020

Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire June 8, 2020

Twist Bioscience Announces Pricing of a $100 Million Public Offering of Common Stock

Business Wire June 3, 2020

Twist Bioscience Announces Proposed Public Offering of Common Stock

Business Wire June 3, 2020

Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection

Business Wire June 1, 2020

Twist Bioscience to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 26, 2020

Twist Bioscience to Participate in the UBS Virtual Global Healthcare Conference

Business Wire May 12, 2020